Mission Pharmacal Neosten
Executive Summary
Slow-release sodium fluoride remains under review at FDA for the treatment of osteoporosis. A Nov. 5 National Osteoporosis Foundation guidance citing "conflicting and controversial" results in reduction of bone fracture refer to sodium fluorides as a class and not specifically to the University of Texas/Mission Pharmacal slow-release formulation ("The Pink Sheet" Nov. 16, p. 21)